Geron(GERN) Prnewswire·2025-04-04 09:45Core Viewpoint - Geron Corporation is facing a class action securities lawsuit due to alleged securities fraud related to the launch and growth potential of its drug Rytelo (imetelstat) between February 28, 2024, and February 25, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Geron misled investors regarding the expectations for Rytelo's market performance, downplaying risks associated with the drug's monitoring requirements and competition [2] - Following the announcement of Geron's fourth-quarter financial results for fiscal 2024 on February 26, 2025, which revealed a flattening growth for Rytelo, the company's stock price dropped from 1.61 per share, a decline of approximately 32.07% in one day [2] Group 2: Investor Actions - Investors who suffered losses during the specified period have until May 12, 2025, to request appointment as lead plaintiff in the lawsuit [3] - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]